{"filing":{"accession_number":"0001193125-26-339147","cik":"0001598646","ticker":"NERV","company_name":"Minerva Neurosciences, Inc.","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-07","primary_document":"d22348d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312526339147/d22348d8k.htm"},"events":[{"id":26122,"run_id":23724,"accession_number":"0001193125-26-339147","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Minerva Neurosciences' financial results for the quarter ended June 30, 2026. The Item 2.02 section explicitly states the company \"issued a press release regarding its financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly and six-month financial results including R\u0026D expense, G\u0026A expense, net income/loss, cash position, and per-share metrics, along with business updates on the Phase 3 roluperidone trial and scientific advisory board formation.","company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27147,"accession_number":"0001193125-26-339147","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Minerva Neurosciences' financial results for the quarter ended June 30, 2026. The Item 2.02 section explicitly states the company \"issued a press release regarding its financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly and six-month financial results including R\u0026D expense, G\u0026A expense, net income/loss, cash position, and per-share metrics, along with business updates on the Phase 3 roluperidone trial and scientific advisory board formation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:08:15.226834+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27147,"accession_number":"0001193125-26-339147","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Minerva Neurosciences' financial results for the quarter ended June 30, 2026. The Item 2.02 section explicitly states the company \"issued a press release regarding its financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains detailed quarterly and six-month financial results including R\u0026D expense, G\u0026A expense, net income/loss, cash position, and per-share metrics, along with business updates on the Phase 3 roluperidone trial and scientific advisory board formation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:08:15.226834+00:00","company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","filing_date":"2026-08-07"}]}